COMMUNIQUÉS West-GlobeNewswire
-
BioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growth
18/06/2026 -
COSCIENS Biopharma Inc. Announces Results of Shareholder Meeting and Appointment of Full-Time CEO
18/06/2026 -
LIXTE Biotechnology Provides Update on NOMAD Acquisition; Transaction Expected to Close On or About July 1, 2026
18/06/2026 -
MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University
18/06/2026 -
Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003
18/06/2026 -
Lite Strategy Leads Strategic Investment in LitVM
18/06/2026 -
Earth Science Tech, Inc. Reports Fiscal Year-End Financial Results for March 31, 2026
18/06/2026 -
CDT Notes Strategic Investment into Sarborg and Expansion into Quantum Computing
18/06/2026 -
NewGen Increases K25.ai Ownership to 10% in Closed Pre-A Round at US$100 Million Valuation with Total US$10 Million Invested
18/06/2026 -
SRx Health Solutions Closes EMJX Acquisition and Launches AI-Driven Platform Strategy Under New Name and Brand, SRX Global, Focused on Investments in High-Conviction Operating Companies and Assets
18/06/2026 -
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
18/06/2026 -
AVITA Medical Highlights First U.K. Clinical Experience with RECELL GO at British Burn Association Annual Meeting
18/06/2026 -
International Myeloma Foundation’s Black Swan Research Initiative Presents Data and Results of Phase 2 ASCENT Cure Trial at EHA 2026 Congress
18/06/2026 -
FDA Approves First Single-Dose Generic Treatment for Influenza
18/06/2026 -
Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease
18/06/2026 -
BIO-Europe unveils renewed vision as the must-attend global biopharma strategy forum
18/06/2026 -
Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares
18/06/2026 -
Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement
18/06/2026 -
New analyses from FIBRONEER™ trials suggest survival benefit with nerandomilast in IPF and PPF
18/06/2026
Pages